Hundreds of people with diabetes are set to benefit from the funding of a new treatment that will help prevent blindness.
From 1 November 2017 dexamethasone implants (brand name Ozurdex) will be funded for eligible people with diabetic macular oedema (DMO), a serious complication of type 1 and type 2 diabetes that can cause blindness if untreated.
Article based on an interview with Prof. Keith Petrie about generic medicines and how prescribers’ own views about generic medicines can affect patient outcomes.
Thousands of children a year are set to avoid chickenpox infection, with flow-on benefits to families and the wider health system, after the varicella vaccine which prevents chickenpox is funded from 1 July 2017.
PHARMAC has announced the funding of five new treatments and wider use of over 30 existing treatments, which are set to benefit many New Zealanders from 1 July 2017.
PHARMAC is pleased to confirm a long-term supply for metoprolol succinate. From 1 March 2018, AstraZeneca will be the sole-supplier of metoprolol succinate in New Zealand, with its brand Betaloc-CR.
A series of 38 funding proposals across the breadth and scope of PHARMAC’s work has been released for public feedback.
A new strategy for Pacific health provides an exciting opportunity to improve the health of Pacific people in New Zealand, says PHARMAC Chief Executive Steffan Crausaz.
Twenty years after it was first tendered, new funding decisions for paracetamol are still making a difference.
Funded influenza vaccinations will be available from more community pharmacies this year.
Researchers from Auckland and Otago Universities are the first recipients of new grants from PHARMAC and the Health Research Council of New Zealand (HRC).
PHARMAC has received a funding application for sanitary pads and tampons.
One of New Zealand’s leading experts in transplant medicine is one of three senior doctors joining PHARMAC’s clinical advisory committee, PTAC.
When it comes making a difference in people’s lives, it’s not about how many medicines you have, but having the ones that work, says PHARMAC Chief Executive Steffan Crausaz.
PHARMAC has announced a major funding package with Roche for nine medicines covering ten different conditions.
The 2016/17 annual tender has been released and PHARMAC is inviting suppliers to submit bids on over 500 products by 15 December 2016.
PHARMAC is pleased to announce a new partnership to support prescribing decisions and promote the responsible use of medicines, says PHARMAC Deputy Medical Director, Dr Bryan Betty.
PHARMAC helps New Zealanders live healthier and better lives, everyday.
PHARMAC is entering a new phase of its national hospital medical device contracting, as it implements the first market share contracts for a set of wound care products.
Steffan Crausaz, PHARMAC Chief Executive, would like to take the time to wish pharmacists from all over New Zealand #happyworldpharmacistsday for Sunday 25 September.
PHARMAC is asking New Zealanders to help it make some changes to how medicine and medical device funding applications are made.